お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:去勢抵抗性前立腺がん (CRPC) 治療の世界市場:2020~2027年
市場調査レポート
商品コード
983135

去勢抵抗性前立腺がん (CRPC) 治療の世界市場:2020~2027年

Global Castrate Resistant Prostate Cancer Therapeutics Market, Size, Share, Opportunities and Forecast, 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=112.06円
去勢抵抗性前立腺がん (CRPC) 治療の世界市場:2020~2027年
出版日: 2021年04月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

去勢抵抗性前立腺がん (CRPC) を含む前立腺がんの有病率の上昇は、市場の成長を拡大させます。さらに、高齢者人口の増加は、市場の主な促進要因となっています。ただし、去勢抵抗性前立腺がん (CRPC) の治療に関連する高コストは、予測期間中の市場の成長の主な抑制要因となっています。

当レポートでは、世界の去勢抵抗性前立腺がん (CRPC) 治療市場について調査分析し、市場の概要、市場成長への影響要因、各セグメント・地域別による市場規模と前年比成長、および主要企業などについて分析しています。

目次

第1章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:調査手法・範囲

  • 調査手法
  • 調査目的と調査範囲

第2章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:市場定義・概要

第3章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:エグゼクティブサマリー

  • 市場内訳:治療タイプ別
  • 市場内訳:ドラッグデリバリー法別
  • 市場内訳:地域別

第4章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以降または将来のシナリオ
  • Covid-19期間中の価格ダイナミクス
  • 需要と供給のスペクトル
  • パンデミック期間中の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:治療タイプ別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):治療タイプ別
  • 市場魅力指数:治療タイプ別
    • 化学療法
    • ホルモン療法
    • 免疫療法
    • 放射線療法

第8章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:ドラッグデリバリー法別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):ドラッグデリバリー法別
  • 市場魅力指数:ドラッグデリバリー法別
    • 経口
    • 注射剤

第9章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:地域別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):地域別
  • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析および前年比成長分析(%):治療タイプ別
    • 市場規模分析および前年比成長分析(%):ドラッグデリバリー法別
    • 市場規模分析および前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第10章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第11章 企業プロファイル

  • Astellas Pharma, Inc.
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主なハイライト
    • 財務概要
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Glaxosmithkline PLC
  • Northwest Biotherapeutic
  • Active Biotech AB
  • Spectrum Pharmaceuticals
  • Abbott Laboratories

第12章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:重要考察

第13章 世界の去勢抵抗性前立腺がん (CRPC) 治療市場:DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次

Global Castrate Resistant Prostate Cancer Therapeutics Market is segmented By Therapy Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Drug Delivery Method (Oral, Injectable), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Castrate Resistant Prostate Cancer Therapeutics Market is expected to grow at a CAGR of 8.4% during the forecasting period (2020-2027).

Castration-resistant prostate cancer is stated as prostate cancer that is scattered to other parts of the body. There are several risk factors for castration-resistant prostate cancer, including genetic predisposition, unhygienic diet, geriatric population, medication exposure, and many sexual partners. The methods were available for the diagnosis for detection of castration-resistant prostate cancer, which includes prostate imaging, tumor marker, biopsy, and staging test. For CRPC treatment, docetaxel-based chemotherapy has been widely accepted by urologists and oncologists.

Market Dynamics

The increasing prevalence of prostate cancer, including castration-resistant prostate cancer, augments the market growth. Moreover, the increasing geriatric population is the main driver of the market. However, the high cost associated with castrate-resistant prostate cancer treatment is the major restraint for the market's growth during the forecast period.

The growing prevalence of prostate cancer leads to the market's growth.

The rising incidences of prostate cancer globally are spurring the market growth for prostate cancer therapeutics. The recorded number of new incidences of prostate cancer in 2017 in the US is approximately 161,300, and the mortalities estimated are around 26,700. Globally prostate cancer is the fourth most common cancer in men.  In every 7 men, there is 1 incidence of male prostate cancer. Prostate cancer cases are more common in older men, accounting for almost 60% of prostate cancer cases diagnosed in men aged 65 or older. 90% of cases occur in men 50 years and older and are uncommon before age 40. Western developed nations have a higher prevalence of prostate cancer cases than in developing nations.

Cancer patients' growth leads to increased demand for castrate-resistant prostate cancer therapeutics to minimize the risk of death and lower the virus's effect on the tumor. The global market consumers are highly health-conscious and ready to spend high amounts to enhance their severe health conditions. The growth in the consumers' average purchasing power and rising cancer prevalence will fuel the demand for castrate-resistant prostate cancer therapeutics globally during the forecast period.

Several drug approvals for castrate-resistant prostate cancer

The governments' focus on the marketing of castrate-resistant prostate cancer therapeutics is increasing considerably across the globe. There are several recent developments noticed in the castrate-resistant prostate cancer therapeutics market, such as-.

In December 2019, Astellas Pharma announced the US FDA approval for XTANDI (enzalutamide) to treat metastatic castration-sensitive prostate cancer. With this approval, the company can provide oral treatment approved by the FDA in three distinct types of advanced prostate cancer, including non-metastatic and metastatic castration-resistant prostate cancer (CRPC) mCSPC.

In July 2019, Bayer AG got the US FDA approval for Nubeqa (darolutamide) to treat non-metastatic castration-resistant prostate cancer (nmCRPC). With this approval, the company expanded its product portfolio of prostate cancer treatment solutions.

Such approvals are expected to drive the growth of the castrate-resistant prostate cancer therapeutics market during the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic outbreak is expected to derail the growth of the castrate-resistant prostate cancer therapeutics market in 2020. The decline in the diagnosis rate due to the downfall in the number of hospital visits is the major factor that has negatively impacted the castrate-resistant prostate cancer therapeutics market growth in 2020.

Market Segment Analysis

The castrate-resistant prostate cancer therapeutics market is classified into oral drug delivery methods and injectable drug delivery methods by drug delivery method.

The oral drug delivery method leads the growth of the market. 

The oral drug delivery method contributes a major share in the castrate-resistant prostate cancer therapeutics market. The doctors majorly suggest oral medicines as compared to injectables for the treatment of castrate-resistant prostate cancer. The market players are also engaged in the marketing of oral castrate-resistant prostate cancer therapeutics across the globe.

By therapy type, the castrate-resistant prostate cancer therapeutics market is classified into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy.

Hormonal therapy segment to dominate global castrate-resistant prostate cancer therapeutics market

Hormone therapy is often regarded as an androgen suppression therapy. The therapy aims to block or lower testosterone in the body to stop them from fueling prostate cancer cells' growth. Lowering androgen levels often makes prostate cancers grow sluggish. Based on drugs' functioning, hormonal therapy is of different types that include orchiectomy and medical castration. Medical castration involves the luteinizing hormone-releasing hormone (LHRH) agonist drugs that lower the amount of testosterone made by the testicles. Leuprolide, Goserelin, Triptorelin, and Histrelin are the commonly used LHRH agonist drugs available in the US market.

Geographical Analysis

North America dominated the global market throughout the forecast period.

The North American market dominated with the largest market share in the global castrate-resistant prostate cancer therapeutics market in 2019. Factors augmenting the North American market's growth include a significant rise in the incidence and prevalence of prostate cancer and the initiatives to create awareness for prostate cancer. For instance, Prostate Cancer Awareness Month is observed in the US and Canada in September every year. Also, the organizations offer grants for prostate cancer research.

Moreover, the Asia Pacific region is expected to grow at the highest CAGR in the global market owing to the high prevalence of prostate cancer in the region coupled with the rapidly evolving healthcare infrastructure in major economies such as China and India are fueling the growth of the castrate-resistant prostate cancer therapeutics market.

Competitive Landscape 

The castrate-resistant prostate cancer therapeutics market is dominating by a few companies. Some of the key players in the market's growth include Astellas Pharma, Inc., Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Northwest Biotherapeutic, and Active Biotech AB, among others. The key players execute several growth strategies such as product launches, acquisitions, and collaborations, which are estimated to boost the castrate-resistant prostate cancer therapeutics market growth globally.  

Astellas Pharma, Inc. 

Overview: Astellas Pharma was founded in 2005 and is headquartered in Tokyo, Japan. It is a pharmaceutical company engaged in the therapeutic fields of oncology, urology, immunology, including infectious diseases and transplantation, neuroscience and diabetes mellitus complications, and metabolic diseases. The company researches, develop, produces, and promotes its prescription medications through subsidiaries in the US, Europe, and Asia. The company offers PADCEV (enfortumab vedotin-ejfv), a treatment for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting. It was launched in the US in December 2019.

Product Type Portfolio: The company's portfolio is comprised of XTANDI.

Why Purchase the Report?

Visualize the composition of the castrate-resistant prostate cancer therapeutics market segmentation by therapy type, drug delivery method, and region, highlighting the key commercial assets and players.

Identify commercial opportunities in the castrate-resistant prostate cancer therapeutics market by analyzing trends and co-development deals. 

Excel data sheet with thousands of data points of castrate-resistant prostate cancer therapeutics market - level 2 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. 

Product mapping in excel for the key product of all major market players

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Related Topic's

Skin Cancer Market

Bone Cancer Market

Breast Cancer Diagnostics Market

Table of Contents

Table of Contents

Castrate Resistant Prostate Cancer Therapeutics Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Castrate Resistant Prostate Cancer Therapeutics Market - Market Definition and Overview

Castrate Resistant Prostate Cancer Therapeutics Market - Executive Summary

Market Snippet by Therapy Type

Market Snippet by Drug Delivery Method

Market Snippet by Region

Castrate Resistant Prostate Cancer Therapeutics Market-Market Dynamics

Market Impacting Factors

Drivers

Rising prevalence of castrate-resistant prostate cancer

Increasing spending on healthcare

Restraints:

Lack of standard therapy  

Opportunity

Impact Analysis

Castrate Resistant Prostate Cancer Therapeutics Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Value Chain Analysis

PEST Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Patent Trends

Castrate Resistant Prostate Cancer Therapeutics Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Castrate Resistant Prostate Cancer Therapeutics Market - By Therapy Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment.

Market Attractiveness Index, By Therapy Type Segment

Chemotherapy

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Hormonal Therapy

Immunotherapy

Radiotherapy

Castrate Resistant Prostate Cancer Therapeutics Market - By Drug Delivery Method

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method Segment.

Market Attractiveness Index, By Drug Delivery Method Segment

Oral

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Injectable

Castrate Resistant Prostate Cancer Therapeutics Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

The U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

The U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

The Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Castrate Resistant Prostate Cancer Therapeutics Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Castrate Resistant Prostate Cancer Therapeutics Market- Company Profiles

Astellas Pharma, Inc.*

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

Bayer AG

Johnson & Johnson Services Inc.

Pfizer Inc.

Sanofi SA

GlaxoSmithKline PLC

Northwest Biotherapeutic

Active Biotech AB

Spectrum Pharmaceuticals

Abbott Laboratories

Other Companies(*LIST NOT EXHAUSTIVE)

Castrate Resistant Prostate Cancer Therapeutics Market - Premium Insights

Castrate Resistant Prostate Cancer Therapeutics Market - DataM Intelligence

Appendix

About Us and Services

Contact Us

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.